West Pharmaceutical Services (FRA:WPS) 3-Month Share Buyback Ratio : 0.69% (As of Mar. 2025 )

View and export this data going back to 2010. Start your Free Trial

What is West Pharmaceutical Services 3-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. West Pharmaceutical Services's current 3-Month Share Buyback Ratio was 0.69%.

Competitive Comparison of West Pharmaceutical Services's 3-Month Share Buyback Ratio

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

West Pharmaceutical Services's 3-Month Share Buyback Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's 3-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

West Pharmaceutical Services 3-Month Share Buyback Ratio Calculation

West Pharmaceutical Services's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2025 is calculated as

3-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2024 )	-	Shares Outstanding (EOP) (Mar. 2025 ))	/	Shares Outstanding (EOP) (Dec. 2024 )
	=	(72.300	-	71.800)	/	72.300
	=	0.69%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

West Pharmaceutical Services (FRA:WPS) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

West Pharmaceutical Services 3-Month Share Buyback Ratio Related Terms

West Pharmaceutical Services Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (FRA:WPS) » Definitions » 3-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

WST:USA WPS:Germany W2ST34:Brazil

Address

530 Herman O. West Drive, Exton, PA, USA, 19341-1147

Website

https://www.westpharma.com

West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.